%PDF-1.4
%
52 0 obj
<>
endobj
49 0 obj
<>
endobj
115 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T11:09:31Z
2024-03-28T18:13:59-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T18:13:59-07:00
application/pdf
Heather
2001-721.oct02
uuid:1c952b14-1dd2-11b2-0a00-ac0927bd7200
uuid:1c952b16-1dd2-11b2-0a00-880000000000
endstream
endobj
38 0 obj
<>
endobj
39 0 obj
<>
endobj
53 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
26 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
142 0 obj
[147 0 R]
endobj
143 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 10 0 0 10 54 713.1616 Tm
(ACKNOWLEDGMENT)Tj
/TT1 1 Tf
0 Tc 0.33929 Tw 8 0 0 8 54 703.1616 Tm
[(W)80 (e are grateful to )55 (Ann )18 (T)35 (ierney for typing the manuscript, Dorothy)]TJ
0.09821 Tw 0 -1.25 TD
(McKnight for statistical analysis and computing help, and all health car\
e)Tj
-0.00011 Tc 0.0137 Tw T*
(professionals who assisted in the care of these patients. Drs. Norris Re\
nnie)Tj
0 Tc -0.01939 Tw T*
(and David Spencer helped establish the original study and Drs. Liz Murph\
y)Tj
0.02499 Tw T*
(and John Hunter were co-authors in the 10 year followup.)Tj
/TT0 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 54 639.1616 Tm
(REFERENCES)Tj
/TT1 1 Tf
0.02499 Tw 8 0 0 8 61 629.1616 Tm
[(1.)-875 (Mitchell DM, Spitz PW)92 (, )37 (Y)100 (oung DY)129 (, Bloch DA, McShane DJ, Fries)]TJ
0 Tc 1.675 -1.25 Td
[(JF)80 (. Survival, prognosis and causes of death in rheumatoid arthritis.)]TJ
T*
(Arthritis Rheum 1986;29:706-14.)Tj
-1.675 -1.25 Td
[(2.)-875 (W)80 (olfe F)80 (, Mitchell DM, Sibley JT)74 (, et al. )18 (The mortality of rheumatoid)]TJ
1.675 -1.25 Td
[(arthritis. )55 (Arthritis Rheum 1994;37:481-94.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875 (McEntegart )55 (A, Morrison E, Capell HA, et al. Ef)18 (fect of social )]TJ
0 Tc 1.675 -1.25 Td
(deprivation on disease severity and outcome in patients with)Tj
T*
[(rheumatoid arthritis. )55 (Ann Rheum Dis 1997;56:410-3.)]TJ
-1.675 -1.25 Td
[(4.)-875 (Myllykangas-Luosujarvi R, )55 (Aho K, Iosmaki H. Death attributed to)]TJ
1.675 -1.25 Td
(antirheumatic medication in a nationwide series of 1666 patients)Tj
T*
(with rheumatoid arthritis who have died. J Rheumatol)Tj
0 Tw T*
(1995;22:2214-7.)Tj
-0.00011 Tc 0.0249 Tw -1.675 -1.25 Td
[(5.)-875 (Fries JF)80 (, Spitz P)111 (, Kraines RG, Holman HR. Measurement of patient)]TJ
0 Tc 1.675 -1.25 Td
[(outcome in arthritis. )55 (Arthritis Rheum 1980;23:137-45.)]TJ
-1.675 -1.25 Td
[(6.)-875 (Bird HA. Longterm safety monitoring in rheumatoid arthritis. )55 (A)]TJ
1.675 -1.25 Td
[(proposal from OMERACT)74 (. J Rheumatol 2000;27:831-3.)]TJ
-1.675 -1.25 Td
[(7.)-875 (Lipani JA, Strand )18 (V)129 (, )18 (W)80 (oodworth )18 (T)74 (, et al. )55 (A)-220 (proposal for developing)]TJ
1.675 -1.25 Td
[(a lar)18 (ge patient population cohort for longterm safety monitoring in)]TJ
T*
(rheumatoid arthritis. J Rheumatol 2000;27:826-30.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875 (Capell HA, Hunter JA, Rennie JAN, Murdoch RM. )]TJ
0 Tc 1.675 -1.25 Td
[(Levamisole \227 )55 (A)-220 (possible alternativbe to gold and penicillamine in)]TJ
T*
(the longterm treatment of rheumatoid arthritis? J Rheumatol)Tj
0 Tw T*
(1981;8:730-40.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875 (Capell HA, Murphy EA, Hunter JA. Rheumatoid arthritis:)]TJ
0 Tc 1.675 -1.25 Td
[(W)80 (orkload and outcome over 10 years. Q J Med 1991;79:461-76.)]TJ
-2.175 -1.25 Td
[(10.)-875 (Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an)]TJ
-0.00011 Tc 2.175 -1.25 Td
(articular index for the assessments of joint tenderness in patients)Tj
0 Tc T*
(with rheumatoid arthritis. Q J Med 1968;37:393-406.)Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Lee P)111 (, Jasani MK, Dick )18 (WC, Buchanan )18 (WW)92 (. Evaluation of a)]TJ
2.1381 -1.25 Td
(functional index in rheumatoid arthritis. Scand J Rheumatol)Tj
0 Tw T*
(1973;2:71-7.)Tj
0.02499 Tw 30.825 48.171 Td
[(12.)-875 (Carstairs )18 (V)129 (, Morris R. Deprivation and health in Scotland.)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Aberdeen: )55 (Aberdeen University Press; 1991.)]TJ
0 Tc -2.175 -1.25 Td
[(13.)-875 (Y)100 (elin E, )18 (W)80 (anke LE. )55 (An assessment of the annual and long-term)]TJ
2.175 -1.25 Td
(direct costs of rheumatoid arthritis: the impact of poor function and)Tj
T*
[(functional decline. )55 (Arthritis Rheum 1999;42:1209-18.)]TJ
-2.175 -1.225 Td
[(14.)-875 (Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic )]TJ
2.175 -1.225 Td
(consequence of the progression of rheumatoid arthritis in Sweden.)Tj
0 -1.225 TD
(Arthritis Rheum 1999;42:347-56.)Tj
-2.175 -1.225 Td
[(15.)-875 (Crilly )55 (A, Maiden N, Capell HA, Madhok R. Predictive value of)]TJ
2.175 -1.225 Td
[(interleukin 1 gene polymorphisms for sur)18 (gery)65 (. )55 (Ann Rheum Dis)]TJ
0 Tw T*
(2000;59:695-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(16.)-875 (Plant MJ, )18 (W)40 (illiams )55 (AL, O\222Sullivan MM, Lewis P)92 (A, Coles EC,)]TJ
0 Tc 2.175 -1.225 Td
(Jessop JD. Relationship between time-integrated C-reactive protein)Tj
T*
(levels and radiologic progression in patients with rheumatoid)Tj
T*
[(arthritis. )55 (Arthritis Rheum 2000;43:1473-7.)]TJ
-0.00011 Tc -2.175 -1.225 Td
[(17.)-875 (Porter DP)111 (, Capell HA, McInnes I, et al. Is rheumatoid arthritis)]TJ
0 Tc 2.175 -1.225 Td
(becoming a milder disease? or are we starting second-line therapy)Tj
T*
(in patients with milder disease? Br J Rheumatol 1996;35:1305-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875 (Graudal N, )18 (T)70 (arp U, Jurik )55 (AG, et al. Inflammatory patterns in)]TJ
0 Tc 2.175 -1.25 Td
(rheumatoid arthritis estimated by the number of swollen and tender)Tj
0 -1.25 TD
(joints, the erythrocyte sedimentation rate, and hemoglobin:)Tj
T*
(Longterm course and association to radiographic progression. J)Tj
T*
(Rhematol 2000;27:47-57.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875 (Jantti J, )55 (Aho K, Kaarela K, Kautiainen H. )18 (W)80 (ork disability in an)]TJ
0 Tc 2.175 -1.25 Td
(inception cohort of patients with seropositive rheumatoid arthritis: a)Tj
T*
[(20 year study)65 (. Rheumatology 1999;38:1)37 (138-41.)]TJ
-2.175 -1.25 Td
[(20.)-875 (W)80 (olfe F)80 (, Zwillich S. )18 (The long-term outcome of rheumatoid arthritis.)]TJ
2.175 -1.25 Td
[(A)-220 (23 year prospective, longitudinal study of total joint replacement)]TJ
T*
(and its predictors in 1,600 patients with rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1998;41:1072-82.)Tj
-2.175 -1.25 Td
[(21.)-875 (Sokka )18 (T)74 (, Hannonen P)111 (. Utility of disease modifying antirheumatic)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(drugs in \223sawtooth\224 strategy)65 (. )55 (A)-220 (prospective study of early)]TJ
0 Tc T*
[(rheumatoid arthritis patients up to 15 years. )55 (Ann Rheum Dis)]TJ
0 Tw T*
(1999;58:618-22.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875 (Gordon P)111 (, )18 (W)80 (est J, Jones H, Gibson )18 (T)74 (. )55 (A)-220 (10 year prospective)]TJ
2.175 -1.25 Td
(follow-up of patients with rheumatoid arthritis 1986-96. J)Tj
0 Tc T*
(Rheumatol 2001;28:2409-15.)Tj
-2.175 -1.25 Td
[(23.)-875 (Chalmers J, Capewell S. Deprivation, disease and death in)]TJ
2.175 -1.25 Td
(Scotland: geographical display of survival of a cohort. BMJ)Tj
0 Tw T*
(2001;323:967-8.)Tj
/TT2 1 Tf
0.02499 Tw -35.4875 -36.3931 Td
[(Capell, et al: RA)-257 (survival after 20 years)]TJ
0 Tw 60.9375 -0.0313 Td
(2105)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
104.25 58.54 407.5 -10.83 re
f*
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
0.5 w
104.25 58.54 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
76 0 obj
<>
endobj
121 0 obj
<>
endobj
30 0 obj
<>
endobj
57 0 obj
<>
endobj
55 0 obj
<>
endobj
56 0 obj
<>
endobj
70 0 obj
<>stream
HVpTι&B$$b5<Y
H`D0)
,JTҡyXa)DA{MxL{q$ ڡ
&<˿~
`jW*/|J?cq,m_ڀSgG_\\G2<`hyyidf({ڊÚrE]=P/+Gt 0rTE`Qed||l@Ei{[|U[XeݤrAi?dB:*AJ ܬB+e$s{hP7WрHHVC. z@bV0
s8FTxqԗ0aac4cgbqP['oDUu,anfZFbՌ:/ˉ6a9'p 1y